<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422019000100037</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticoagulación en poblaciones especiales con fibrilación auricular]]></article-title>
<article-title xml:lang="en"><![CDATA[Anticoagulation in populations special with atrial fibrillation]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Juanatey]]></surname>
<given-names><![CDATA[José R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez Álvarez]]></surname>
<given-names><![CDATA[Belén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universitario de Santiago de Compostela Hospital Clínico ]]></institution>
<addr-line><![CDATA[A Coruña ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universitario de Santiago de Compostela Servicios de Cardiología del Hospital Clínico ]]></institution>
<addr-line><![CDATA[A Coruña ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<numero>1</numero>
<fpage>37</fpage>
<lpage>40</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422019000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422019000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422019000100037&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La seguridad y eficacia de los anticoagulantes directos se ha demostrado como alternativas al tratamiento con antagonistas de la vitamina K en pacientes con fibrilación auricular (FA), permitiendo realizar una cardioversión precoz, especialmente en los pacientes tratados con Rivaroxabán y Edoxabán. Los pacientes con FA presentan un riesgo tromboembólico elevado, que varía según el número de factores de riesgo asociados. Además de esas características intrínsecas de cada individuo, el procedimiento de ablación puede presentar un incremento de eventos, en relación a la introducción y manipulación de catéteres, la presencia de introductores dentro de la aurícula izquierda y las lesiones endocárdicas producidas por la ablación. Por lo que es fundamental mantener la anticoagulación durante este procedimiento. Un tercer aspecto importante a tener en cuenta es el manejo perioperatorio de estos casos. El tiempo previo para suspender la terapia anticoagulante depende de cada fármaco, no se requiere puente con heparinas de bajo peso molecular y para el manejo de posibles sangrados existen algoritmos que analizaremos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The safety and efficacy of direct anticoagulants has been demonstrated as alternatives to treatment with vitamin K antagonists in patients with atrial fibrillation (FA), allowing early cardioversion, especially in patients treated with Rivaroxaban and Edoxaban. Patients with AF have a high thromboembolic risk, which varies according to the number of associated risk factors. In addition to the intrinsic risk of each individual, the ablation procedure presents an increased risk of events, in relation to the introduction and manipulation of catheters, the presence of sheaths inside the left atrium and the endocardial lesions produced by ablation. For this reason, it is essential to maintain anticoagulation during this procedure. Finally, we present some aspects about the management in the perioperative period in this patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[cardioversión]]></kwd>
<kwd lng="es"><![CDATA[ablación]]></kwd>
<kwd lng="es"><![CDATA[NOAC]]></kwd>
<kwd lng="en"><![CDATA[atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[cardioversion]]></kwd>
<kwd lng="en"><![CDATA[ablation]]></kwd>
<kwd lng="en"><![CDATA[NOAC]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Benussi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kotecha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ahlsson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Casadei]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS.]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Le Heuzey]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<numero>47</numero>
<issue>47</issue>
<page-range>3346-55</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidbuchel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Verhamme]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alings]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Antz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Diener]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Hacke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated European Heart Rhythm Association practical guide on the use of nonvitamin K antagonist anticoagulants in patients with nonvalvular atrial fibrillation.]]></article-title>
<source><![CDATA[Europace]]></source>
<year>2015</year>
<volume>17</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1467-507.</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Marchlinski]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Hohnloser]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Naccarelli]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Xiang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wilber]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in nonvalvular atrial fibrillation.]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2015</year>
<volume>36</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>1805-11</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
